The Enigma of PCSK9 Regulation: Leveraging Therapeutics Towards Mechanistic Understanding
- PMID: 34593127
- DOI: 10.1016/j.jacc.2021.08.006
The Enigma of PCSK9 Regulation: Leveraging Therapeutics Towards Mechanistic Understanding
Keywords: LDL cholesterol; LDL receptor; PCSK9; cholesterol homeostasis; monoclonal antibodies; turnover studies.
Conflict of interest statement
Funding Support and Author Disclosures Dr Rosenson has received research funding to his institution from Amgen, National Institutes of Health, Novartis, and Regeneron; has received consulting fees from Amgen, Amyrt, C5, CVS Caremark, Regeneron, and 89Bio; has received nonpromotional speaker fees from Amgen, Kowa, and Regeneron; has received royalties from Wolters Kluwer (UpToDate); and has stock holdings in MediMergent. Dr Goonewardena has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.J Am Coll Cardiol. 2021 Oct 5;78(14):1437-1449. doi: 10.1016/j.jacc.2021.07.056. J Am Coll Cardiol. 2021. PMID: 34593126 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous